Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody | DRUG | - |
Inclusion Criteria: * Diagnosis of diffuse systemic sclerosis * Duration of disease 18 months or less * Modified Rodnan Skin Score in a range as identified by the study protocol * Evidence of worsening disease activity * Ability to attend follow-up assessments for a minimum of 9 months * Agree to d...
Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody is an investigational monoclonal antibody developed by Sanofi for systemic sclerosis, also known as scleroderma. It was studied in early stage diffuse systemic sclerosis. The compound is also known by the code name CAT-192.
It was studied for the treatment of early stage diffuse systemic sclerosis, a form of scleroderma. The single clinical trial enrolled patients with systemic sclerosis and scleroderma. It is an investigational agent and is not an approved therapy for this or any other indication.
Sanofi, which trades under the ticker SNY, is the developer of Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody. The antibody is also identified by the code name CAT-192.
Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody is in Phase 1 development. Its only recorded trial, NCT00043706, is a completed Phase 1 study, and no active trials are ongoing. It is an investigational drug and has not been approved by the FDA.
One clinical trial has evaluated Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody: NCT00043706, a completed Phase 1 study titled Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis. It was conducted in the United States in adults aged 18 years and older.
Yes. CAT-192 is an alternative name for Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody. The Phase 1 trial NCT00043706 refers to the drug as CAT-192, so searches for either name refer to the same Sanofi monoclonal antibody candidate.